GeneDx Holdings Corp. (NASDAQ:WGS) Given Average Rating of “Moderate Buy” by Analysts

GeneDx Holdings Corp. (NASDAQ:WGS) has earned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $150.7143.

Several brokerages have commented on WGS. BTIG Research dropped their price target on shares of GeneDx from $200.00 to $170.00 and set a “buy” rating on the stock in a research note on Tuesday. Wall Street Zen cut GeneDx from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Piper Sandler reaffirmed an “overweight” rating and set a $130.00 target price (down from $160.00) on shares of GeneDx in a research note on Tuesday. Wells Fargo & Company upgraded GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 price target for the company in a research report on Monday, February 9th. Finally, Zacks Research raised GeneDx from a “hold” rating to a “strong-buy” rating in a report on Wednesday.

GeneDx Stock Performance

WGS stock opened at $79.71 on Friday. GeneDx has a 1 year low of $55.17 and a 1 year high of $170.87. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -106.28 and a beta of 2.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.59 and a current ratio of 2.46. The stock’s fifty day moving average is $106.45 and its two-hundred day moving average is $123.65.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Monday, February 23rd. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $120.99 million for the quarter, compared to analysts’ expectations of $120.80 million. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. On average, research analysts predict that GeneDx will post 0.97 EPS for the current year.

Insiders Place Their Bets

In other news, COO Bryan Dechairo sold 5,961 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $85.70, for a total value of $510,857.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Kevin Feeley sold 317 shares of the stock in a transaction that occurred on Thursday, January 29th. The shares were sold at an average price of $93.99, for a total transaction of $29,794.83. Following the completion of the transaction, the chief financial officer owned 9,168 shares of the company’s stock, valued at $861,700.32. This trade represents a 3.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 30,961 shares of company stock worth $3,933,831. 29.60% of the stock is owned by corporate insiders.

Institutional Trading of GeneDx

Institutional investors have recently modified their holdings of the company. Kestra Advisory Services LLC bought a new position in shares of GeneDx during the 4th quarter valued at about $27,000. Jones Financial Companies Lllp raised its holdings in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares in the last quarter. Ramirez Asset Management Inc. acquired a new stake in GeneDx during the fourth quarter valued at approximately $33,000. Greenline Wealth Management LLC bought a new stake in GeneDx during the fourth quarter worth approximately $33,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in GeneDx in the fourth quarter worth approximately $35,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.